Professor Sarah Danson

All publications

Journal articles

• Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A , Hill MS et al (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15-E15.
• Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I , Steven N et al (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202, 114009-114009.
• Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B , Carser J et al (2024) A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). European Journal of Cancer, 196, 113455-113455.
• Hapuarachi B, Danson S, Wadsley J & Muthana M (2023) Exercise to transform tumours from cold to hot and improve immunotherapy responsiveness. Frontiers in Immunology, 14, 1335256.
• Jones RP, Lee LYW, Corrie PG, Danson S & Vimalachandran D (2023) Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial. British Journal of Surgery, 110(12), 1883-1884.
• Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL , Weiss J et al (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), 553-562.
• Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J , Johnson D et al (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616(7957), 534-542.
• Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A , Hill MS et al (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616(7957), 525-533.
• Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C , Toncheva A et al (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616(7957), 543-552.
• Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K , Huebner A et al (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), 833-845.
• Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, Kidd AC, Frankell AM, Watkins TBK, Martínez-Ruiz C , Puttick C et al (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), 846-858.
• Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M , Young G et al (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616(7957), 563-573.
• Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan F-C, Marongiu F, Evans EJ, Moore DA , Rodrigues FS et al (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), 159-167.
• Danson S, Sirois F, Fradley K, Wadsley J, Ray J, Bishop R, Horsman J, Mann C, Chantry-Groves L, Young M & Bentall R (2023) Mental health burden for NHS healthcare staff during the COVID-19 pandemic: First results of a longitudinal survey. Heliyon, 9(3), e13765-e13765.
• Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N , Majem Tarruella M et al (2023) Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. Lung Cancer, 175, 141-151.
• Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G & Casbard A (2022) Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): a multicentre, randomised, controlled, phase 2 trial. eClinicalMedicine, 52.
• Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, Shah R, Bhosle J, Hodgkinson E, Watkins B & Billingham L (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer, 171, 26-33.
• Lee RW, Danson S, Elliot M, Park EI, Pinkney TD, Shaw CE, Vimalachandran D, Maughan T, Seymour M, Corrie P & Wadsley J (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology.
• Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Morton C, Joseph M , Hessey S et al (2022) A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 3(6), 696-709.
• Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L , Gardner G et al (2022) Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine, 48.
• Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P & Nye M (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23(1), e14-e15. View this article in WRRO
• Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L , Lord J et al (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology. View this article in WRRO
• Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe H-S, Bustin F, Crequit J, Coate L, Guillot M , Surmont V et al (2021) Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer, 161, 76-85.
• Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J , Velikova G et al (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21(1). View this article in WRRO
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research.
• Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA , Jamal-Hanjani M et al (2021) Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 597(7877), 555-560.
• Merry E, Marples M, Danson S, Harding D, Denny J, Vazquez I, Chesshire L, Taylor F, Fusi A & Dalgleish A (2020) Effect of carboplatin when administered after dacarbazine failure : clinical benefit of sequential therapy. Molecular and Clinical Oncology, 13(6), 1-4.
• Kennedy F, Shearsmith L, Ayres M, Lindner OC, Marston L, Pass A, Danson S & Velikova G (2020) Online monitoring of patient self-reported adverse events in early phase clinical trials : views from patients, clinicians, and trial staff. Clinical Trials.
• Gomes F, Lewis A, Morris R, Parks R, Kalsi T, Babic-Illamn G, Baxter M, Colquhoun K, Rodgers L, Smith E , Greystoke A et al (2020) The care of older cancer patients in the United Kingdom. ecancermedicalscience, 14.
• Wyld L, Bellantuono I, Tchkonia T, Morgan J, Turner O, Foss F, George J, Danson S & Kirkland JL (2020) Senescence and cancer : a review of clinical implications of senescence and senotherapies. Cancers, 12(8). View this article in WRRO
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot DC, Child J, Farrelly L, Sharkey AJ, Busacca S, Ngai Y , Hackshaw A et al (2020) Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02) : a phase Ib trial. Clinical Cancer Research. View this article in WRRO
• AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M , Zapata L et al (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), 1054-1062.
• Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M , Rodriguez-Abreu D et al (2020) A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC : the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR trial. Journal of Thoracic Oncology. View this article in WRRO
• López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK, Rowan A, Dewhurst SM , Birkbak NJ et al (2020) Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics, 52(3), 283-293.
• Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T , Ronel T et al (2020) Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 26(7), 1148-1148.
• Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L , Greco M et al (2020) Publisher Correction: A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 26(7), 1148-1148.
• Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N , Pierce J et al (2020) Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine, 26(7), 1147-1147.
• Passy L, Silva S, Brock I, Wells G, Cox A & Danson S (2019) 7 Assessing melanoma BRAF status through ddPCR of cfDNA. Postgraduate Medical Journal, 95(1130), 686.4-687.
• Passby L, Silva S, Brock I, Wells G, Cox A & Danson S (2019) Assessing melanoma BRAF status through ddPCR of cfDNA. Annals of Oncology, 30, vii15-vii15.
• Nathan P, Needham A, Corrie PG, Danson S, Evans J, Ochsenreither S, Kumar S, Goodman A, Larkin JMG, Karydis I , Steven NM et al (2019) SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology, 30, v908-v910.
• Danson S, Mulvey MR, Turner L, Horsman J, Escott KJ, Coleman RE, Ahmedzai SH, Bennett MI & Andrew D (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. Journal of Bone Oncology. View this article in WRRO
• Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S & Corrie P (2019) Are we over-treating with checkpoint inhibitors?. British Journal of Cancer, 121(8), 629-630. View this article in WRRO
• Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ , Marshall E et al (2019) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 30(12), 2013-2014.
• Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S , Griffiths R et al (2019) Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. OncoImmunology. View this article in WRRO
• Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C , Goff M et al (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30(2), 317-324. View this article in WRRO
• Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K , Henry JY et al (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature, 567(7749), 479-485.
• Geva R, Lopez JS, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Pereira KMC & Perets R (2018) Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging, 46(5), 1092-1101. View this article in WRRO
• Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V , Barlesi F et al (2018) Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer, 124, 310-316. View this article in WRRO
• Silva S, Danson S, Teare MD, Taylor F, Bradford J, McDonagh A, Salawu A, Wells G, Burghel G, Brock I , Connley D et al (2018) Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clinical chemistry, 64(9), 1338-1346. View this article in WRRO
• Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ , Marshall E et al (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29(8), 1843-1852. View this article in WRRO
• Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J , Ottensmeier C et al (2018) CONFIRM: A double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: Study protocol for a randomised controlled trial. Trials, 19(1). View this article in WRRO
• Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C , Henry JY et al (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33(4), 649-663.e4. View this article in WRRO
• Crabb S, Danson SJ, Catto JWF, McDowell C, Lowder JN, Caddy J, Dunkley D, Rajaram J, Ellis D, Hill S , Hathorn D et al (2018) SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: Study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, 19(1). View this article in WRRO
• Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A , Albanell J et al (2018) Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. OncoImmunology, 7(2), 00-00. View this article in WRRO
• Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V , Barlesi F et al (2018) Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer, 124, 298-309. View this article in WRRO
• McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J , Swanton C et al (2017) Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 171(6), 1259-1271.e11. View this article in WRRO
• Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Quesne JL, Moore DA, Veeriah S, Rosenthal R , Marafioti T et al (2017) Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature, 545, 446-451. View this article in WRRO
• Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A , Ben Aissa A et al (2017) Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 46(4), 577-586. View this article in WRRO
• Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C , Potter V et al (2016) Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 11(9), 1511-1521. View this article in WRRO
• Danson SJ, Rowland C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton MQ, Woll PJ & Eiser C (2016) The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. Supportive Care in Cancer, 24(4), 1507-1516. View this article in WRRO
• Rowland C, Danson SJ, Rowe R, Merrick H, Woll PJ, Hatton MQ, Wadsley J, Ellis S, Crabtree C, Horsman JM & Eiser C (2016) Quality of life, support and smoking in advanced lung cancer patients: a qualitative study.. BMJ Support Palliat Care, 6(1), 35-42.
• Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M , Tulasi V et al (2015) An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of Medicinal Chemistry, 58(23), 9309-9333. View this article in WRRO
• Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K , Rao A et al (2015) Ipilimumab in the real world: The UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25(5), 432-442. View this article in WRRO
• Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M , Gonzalez-Angulo AM et al (2015) Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 75(17), 3479-3491.
• Thomas SJ, Snowden JA, Zeidler MP & Danson SJ (2015) The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. British Journal of Cancer, 113(3), 365-371. View this article in WRRO
• Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S & Zeidler MP (2015) Methotrexate Is a JAK/STAT Pathway Inhibitor. PLOS ONE, 10(7). View this article in WRRO
• Hammond DW, Al-Shammari NSD, Danson S, Jacques R, Rennie IG & Sisley K (2015) High-Resolution Array CGH Analysis Identifies Regional Deletions and Amplifications of Chromosome 8 in Uveal Melanoma. Investigative Opthalmology & Visual Science, 56(6), 3460-3466.
• Thomas S, Fisher K, Snowden J, Danson S, Brown S & Zeidler M (2015) Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. The Lancet, 385, S98-S98.
• Bird J, Coleman P & Danson S (2015) Coping with melanoma-related worry: a qualitative study of the experiences and support needs of patients with malignant melanoma. Journal of Clinical Nursing, 24(7-8), 937-947. View this article in WRRO
• Danson S (2015) Implications and benefits of the NICE appraisal of pembrolizumab. British Journal of Healthcare Management, 21(11), 506-508.
• Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S , Gadgeel SM et al (2014) Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology, 9(11), 1704-1708. View this article in WRRO
• Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M , Danson SJ et al (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.. Lancet Oncol, 15(6), 620-630.
• Khan F, Ottensmeier C, Szabo M, Bates AT, Popat S, Dua D, Dorey N, Ellis S, Upadhyay S, Califano R , Lee L et al (2014) Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer.
• Silva S & Danson S (2013) Targeted Therapy and New Anticancer Drugs in Advanced Disease. Thoracic Surgical Clinics, 23, 411-419.
• Marques CMG, Dibden C, Danson S, Haycock JW & MacNeil S (2013) Combined Effects of Capsaicin and HA14-1 in Inducing Apoptosis in Melanoma Cells. Journal of Cosmetics, Dermatological Sciences and Applications, 3, 175-189.
• O'Brien ME, Gafaar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A , Hasan B et al (2013) Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).. European Journal of Cancer.
• Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan PD et al (2013) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. Journal of Clinical Oncology, 31(15_suppl), 9068-9068.
• Talbot DC, Blackhall FH, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmuller CA, Pinder MC, Mezger J, Danson S , Callies S et al (2013) A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).. Journal of Clinical Oncology, 31(15_suppl), 8051-8051.
• Ahmad S, Qian W, Ellis SG, Khattak MA, Gupta A, Thillai K, Board RE, Nobes J, Dalgleish A, Grumett SA , Maraveyas A et al (2013) Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.. Journal of Clinical Oncology, 31(15_suppl), 3018-3018.
• Walkington LA, Lorigan P & Danson SJ (2013) Advances in the treatment of late stage melanoma.. BMJ, 346, f1265.
• Shankland K, Kirkbride P, Price J, Walkington L & Danson SJ (2012) The acute oncologist's role in managing patients with cancer and other co-morbidities. Journal of Comorbidity, 2(1), 10-17. View this article in WRRO
• Rowland C, Eiser C, Rowe R & Danson S (2012) The effect of smoking on health related quality of life in lung cancer patients: a systematic review. BMJ Supportive and Pallative Care(2), 312-318.
• Thompson R, Meuth M, Woll P, Zhu Y & Danson S (2012) Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.. Int J Oncol, 40(1), 194-202.
• Danson SJ, Quinn AM, Blackhall F, Wilson G, Clamp A, Ashcroft L, Brierley J & Hasleton P (2011) Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.. Histopathology, 61(3)(September 2012), 454-464.
• Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J , Robson L et al (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.. Ann Oncol, 22(7), 1653-1660.
• O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Gonzalez R, Trefzer U, Mohr P , Ottensmeier et al (2011) A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer(105), 346-352.
• O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Gonzalez R, Trefzer U & Mohr P (2011) A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer(105), 346-352.
• Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP & Middleton MR (2011) Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.. Melanoma Res, 21(6), 502-508.
• Wheatley-Price P, Blackhall F, Lee S-M, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R , Danson S et al (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.. Ann Oncol, 21(10), 2023-2028.
• Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R , Morris C et al (2010) Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.. Ann Oncol, 21(4), 884-894.
• Wilson C & Danson SJ (2010) Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 1, 37-51.
• Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J , Dickinson G et al (2009) Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.. J Clin Oncol, 27(10), 1660-1666.
• Danson S, Dean E, Dive C & Ranson M (2007) IAPs as a target for anticancer therapy.. Curr Cancer Drug Targets, 7(8), 785-794.
• Danson S, Ranson M, Denneny O, Cummings J & Ward TH (2007) Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.. Cancer Chemother Pharmacol, 60(6), 851-861.
• O'Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D & Ranson M (2007) Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.. J Clin Oncol, 25(22), 3266-3273.
• Danson S, Johnson P, Ward T, Dawson M, Denneny O, Watson A, Jowle D, Sharpe P, Dive C & Ranson M (2007) Final results of a phase I clinical trial of the bioreductive drug RH1. Journal of Clinical Oncology, 25(18_suppl), 2514-2514.
• Lakshminarayana P, Danson S, Suvarna K & Hancock B (2007) Atrial and placental melanoma metastasis: a case report and literature review.. J Med Case Rep, 1, 21. View this article in WRRO
• Danson SJ, Lakshmiarayana P, Survana K & Hancock B (2007) Atrial and placental melanoma metastasis: a case report and literature review, 1, 21-25.
• Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L & Talbot D (2006) DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. Journal of Thoracic Oncology, 1(9), 984-990.
• Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L & Talbot D (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.. J Thorac Oncol, 1(9), 984-990.
• Welman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD & Dive C (2006) Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.. Neoplasia, 8(11), 905-916.
• Danson S & Lorigan P (2006) Melanoma vaccines--they should work.. Ann Oncol, 17(4), 539-541.
• Baka S, Ranson M, Lorigan P, Danson S, Linton K, Hoogendam I, Mettinger K & Thatcher N (2005) A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.. Eur J Cancer, 41(11), 1547-1550.
• Blackhall F, Papakotoulas PI, Danson S & Thatcher N (2005) Perspectives on novel therapies for bronchial carcinoma.. Expert Opin Pharmacother, 6(7), 1157-1167.
• Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RHJ & Butler J (2005) Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.. Clin Cancer Res, 11(7), 2695-2701.
• Danson S & Lorigan P (2005) Improving outcomes in advanced malignant melanoma: update on systemic therapy.. Drugs, 65(6), 733-743.
• Danson S, Blackhall F, Hulse P & Ranson M (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects.. Drug Saf, 28(2), 103-113.
• Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N , Manegold C et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. LUNG CANCER-J IASLC, 47(1), 69-80.
• Clamp A, Danson S, Nguyen H, Cole D & Clemons M (2004) Assessment of therapeutic response in patients with metastatic bone disease.. Lancet Oncol, 5(10), 607-616.
• Clayton AJ, Danson S, Jolly S, Ryder WDJ, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G , Howell A et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.. Br J Cancer, 91(4), 639-643. View this article in WRRO
• Danson S, Ward TH, Butler J & Ranson M (2004) DT-diaphorase: a target for new anticancer drugs.. Cancer Treat Rev, 30(5), 437-449.
• O'Byrne K, Clarke L, Dunlop D, Ranson M, Danson S, Botwood N & Carbone D (2004) Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology, 22(14_suppl), 7101-7101.
• Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G & Ranson M (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.. Br J Cancer, 90(11), 2085-2091. View this article in WRRO
• Danson S (2004) Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer.. Cancer Treat Rev, 30(3), 309-314.
• Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R , Dowd I et al (2003) Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.. Cancer, 98(3), 542-553.
• Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N & Middleton MR (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.. J Clin Oncol, 21(13), 2551-2557.
• Clamp A, Danson S & Clemons M (2003) Hormonal and genetic risk factors for breast cancer.. Surgeon, 1(1), 23-31.
• Le Chevalier T, Brown A, Fitzgerald P, Aristides M, Natale R, Scagliotti G, Vansteenkiste J, Van Meerbeeck JL, Rosell R, Rudd RM , Danson S et al (2003) A meta-analysis of platinum-based GEMZAR® in non-small cell lung cancer (NSCLC). Revue de Pneumologie Clinique, 59(5 I), 333-335.
• Clamp A, Danson S & Clemons M (2002) Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies.. Lancet Oncol, 3(10), 611-619.
• Clemons M, Danson S & Howell A (2002) Tamoxifen ("Nolvadex"): a review.. Cancer Treat Rev, 28(4), 165-180.
• Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S , Cosford R et al (2002) Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.. J Clin Pharmacol, 42(7), 774-781.
• Danson SJ & Middleton MR (2001) Temozolomide: a novel oral alkylating agent.. Expert Rev Anticancer Ther, 1(1), 13-19.
• Clemons M, Danson S, Hamilton T & Goss P (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival.. Cancer Treat Rev, 27(2), 67-82.
• Zhao A, Maple L, Jiang J, Myers KN, Jones CG, Gagg H, McGarrity-Cottrell C, Rominiyi O, Collis SJ, Wells G , Rahman M et al () SENP3-FIS1 axis promotes mitophagy and cell survival under hypoxia. Cell Death & Disease, 15(12).
• Puttick C, Jones TP, Leung MM, Galvez-Cancino F, Liu J, Varas-Godoy M, Rowan A, Pich O, Martinez-Ruiz C, Bentham R , Dijkstra KK et al () MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution. Nature Genetics.
• Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP , van der Aart J et al () Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature Communications, 15(1).
• Hynds RE, Huebner A, Pearce DR, Hill MS, Akarca AU, Moore DA, Ward S, Gowers KHC, Karasaki T, Al Bakir M , Wilson GA et al () Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. Nature Communications, 15(1).
• Rahman MM, Wells G, Rantala JK, Helleday T, Muthana M & Danson SJ () In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges. Expert Review of Clinical Immunology, 1-18.
• Pan X, AbdulJabbar K, Coelho-Lima J, Grapa A-I, Zhang H, Cheung AHK, Baena J, Karasaki T, Wilson CR, Sereno M , Veeriah S et al () The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer.
• Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al () Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12, 954-954.
• Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN , Veal GJ et al () A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer.
• Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
• Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al () Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 1-48.
• Howard F, Conner J, Danson S & Muthana M () Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Frontiers in Molecular Biosciences, 9.
• Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al () Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.

Chapters

• Danson SJ (2010) Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
• Danson SJ, Teare MD & Woll PJ (2008) Hereditary Tumours- From Genes to Clinical Consequences, Lung Tumours Wiley-VCH
• Danson SJ (2007) Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
• Danson SJ, Blackhall F, Baka S & Ranson M (2006) Novel therapies for mesothelioma, Malignant Pleural Mesothelioma Oxford University Press
• Ranson M & Danson S (2003) Novel targeted approaches to the management of non-small cell lung cancer, Advances in Effective Management of Lung Cancer Aesculopius Medical Press
• Danson S, Teare MD & Woll P () Lung Tumors, Hereditary Tumors (pp. 183-192). Wiley-VCH Verlag GmbH & Co. KGaA

Conference proceedings papers

• Mayland CR, Collinson M, Ahmedzai S, Lucas J, Gath J, Darlison L, Defonseka D, Laird B, Stanley H, Gardiner C , Danson S et al (2024) P216 Unravelling pain in malignant pleural mesothelioma: a longitudinal study. ‘The (Richard) Light Fantastic’ – Pleural disease diagnosis and outcomes (pp A236-A237)
• Shaw HM, Patel PM, Payne M, Kumar S, Danson S, Highley M, Prasad K, Board R, Barlow C, Larkin J , Young K et al (2024) A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab plus ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
• Middleton G, Fletcher P, Savage J, Mehmi M, Greystoke A, Dangoor A, Cave J, Escriu C, Shaw P, Steele N , Jain P et al (2023) MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J. Journal of Thoracic Oncology, Vol. 18(11) (pp S119-S120)
• Shaw H, Patel P, Payne M, Kumar S, Danson S, Highley M, Barlow C, Miller R, Master F & Durrant L (2023) 1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial. Late-Breaking Abstracts
• Middleton G, Marshall L, Billingham L, Duffus KD, Greystoke A, Carter L, Forster MD, Cook N, Hargrave D, Danson S , Roxburgh P et al (2023) 716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers. Annals of Oncology, Vol. 34 (pp S494-S495)
• Rahman MM, Wells G, Rantala J, Helleday T, Muthana M & Danson S (2023) 2302P Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays. Annals of Oncology, Vol. 34 (pp S1177-S1177)
• Shum B, Lobon I, Lesluyes T, Pallikonda H, Khoja LT, Kissoonsingh P, Nahm SH, El Badri S, Peleva E, Fusi A , Gault AC et al (2023) 2236P MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM). Annals of Oncology, Vol. 34 (pp S1151-S1152)
• Gupta A, Matin RN, Dayimu A, Nobes J, Board RE, Payne M, Rao AR, Fusi A, Danson S, Eccles BK , Carser J et al (2023) 1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM). Annals of Oncology, Vol. 34 (pp S669-S670)
• Gagg H, Williams S, Rominiyi O, Danson S, Collis S & Wells G (2023) DEVELOPMENT OF GLIEXP; A HIGH-THROUGHPUT EX VIVO DRUG SCREENING PLATFORM FOR GLIOBLASTOMA. Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
• Ottensmeier CHH, Pinato DJJ, Armstrong AC, Symeonides SN, Patel PM, Danson S, Korolewicz J, Cameron D, Miller RM, Master F , Paston S et al (2023) Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
• Griffiths GO, Griffiths D, Eminton Z, Hill K, Poile C, Nye M, Cave J, Danson S, Toy E, Jain P , Steele N et al (2023) A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
• Guo C, Crabb SJ, Pacey S, Coyle V, Danson S, Villacampa G, Chandran K, Paschalis A, Riisnaes R, Ferreira A , Carreira S et al (2023) A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
• Fennell DA, Ewings S, Hill K, Poile C, Baitei E, Zhou Z, Harber J, Kamata T, Yang H, Dzialo J , Faulkner D et al (2023) Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
• Middleton G, Fletcher P, Savage J, Mehmi M, Greystoke A, Dangoor A, Cave J, Escriu C, Shaw P, Steele N , Jain P et al (2023) A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S119-S120)
• Lefley D, Jones C, Danson S, Bryant H, Collis S, Brown J & Ottewell P (2023) Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
• Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) Ex vivo-led drug discovery in glioblastoma. WFNOS 2022 Abstract Book (pp s240)
• Fennell D, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, Wilding S, Danson S, Nye M, Steele N , Johnson L et al (2021) Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(3) (pp S62-S62)
• Mitchell T, Jones T, Danson S, Glover M, Bury J, Horsman J, Christian L, Hill E, Harrison E, Hatton M & Bryant H (2021) Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S1163-S1164)
• Mitchell T, Astley J, Robinson S, Bryant H, Danson S, Tahir B & Hatton M (2021) Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S958-S958)
• Crabb SJ, Huddart RA, Brown E, Dunkley D, Downs N, McDowell C, Catto JWF, Griffiths GO, Danson S & Reid AH (2020) Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
• Fennell DA, Lester JF, Danson S, Blackhall FH, Nicolson M, Nixon LS, Porter C, Gardner GM, White A, Griffiths GO & Casbard AC (2020) A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
• Nathan P, Needham A, Corrie PG, Danson S, Evans J, Ochsenreither S, Kumar S, Goodman A, Larkin JMG, Karydis I , Steven NM et al (2019) SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). ANNALS OF ONCOLOGY, Vol. 30
• Elmushraf R, Clinch H, Salawu A, Fisher P, Young R, Lee C, Danson S, Bates E, Hatton M, Low L , Das T et al (2019) The North Trent experience of the use of first line pembrolizumab in stage IIIB/IV non-small cell lung cancer. Lung Cancer, Vol. 127 (pp S43-S43)
• Danson S, Plummer R, Ottensmeier C, Hook J, Marshall H, Sagoo G, Meads D, Bestall J, Velikova G, Gallagher F , Smith A et al (2019) A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. BRITISH JOURNAL OF CANCER, Vol. 121 (pp 23-23)
• Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29
• Bird J, Nolan M & Danson SJ (2018) CN23 Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals. Annals of Oncology, Vol. 29(suppl_8) (pp viii688-viii688), 19 October 2018 - 23 October 2018. View this article in WRRO
• Peters S, Danson SJ, Hasan B, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D , Falchero L et al (2018) A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Annals of Oncology, Vol. 29 (pp viii498-viii498)
• Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. Annals of Oncology, Vol. 29 (pp viii139-viii139)
• Fennell D, Danson S, Forster M, Talbot D, Woll P, Child J, Ngai Y, Farrelly L, Hackshaw A, Sharkey A , Busacca S et al (2018) MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. Journal of Thoracic Oncology, Vol. 13(10) (pp S397-S397)
• Fennell DA, Kirkpatrick EV, Cozens K, Danson S, Hanna GG, Lester JF, Lord J, Nye M, Ottensmeier CHH, Szlosarek PW , Steele NL et al (2018) CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS8586-TPS8586)
• Crabb SJ, Danson S, Catto J, McDowell C, Dunkley D, Huddart RA & Griffiths G (2018) SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594)
• Wells G, Kohlmann A, Ratcliffe M, Wilson G, Dalton A & Danson S (2018) Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC). European Journal of Surgical Oncology, Vol. 44 (pp S36-S36)
• Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2018) Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 44 (pp S26-S27)
• Danson SJ, Perets R, Lopez J, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger B, Pereira KMC & Geva R (2018) Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup. Poster Session Abstracts
• Garikipati S, Prakash A, Alhilali M, Burnett A, Lee C, Young R, Danson S, Bates E, Fisher PM, Hatton MQ & Das T (2018) Management and outcomes of patients with small cell lung cancer in North Trent. Lung Cancer, Vol. 115 (pp S73-S73) View this article in WRRO
• Low L, Salawu A, Bates E, Young R, Danson S, Fisher PM, Hatton MQ, Lee C, Das T & Taylor F (2018) The North Trent experience of administering pembrolizumab to previously treated patients with advanced non-small cell lung cancer. Lung Cancer, Vol. 115(Suppl 1) (pp S35-S35), 24 January 2018 - 26 January 2018. View this article in WRRO
• Hanna G, Griffiths G, Kirkpatrick EV, Cozens K, Kalevras M, Maishman T, Danson S, Lester J, Ottensmeier C, Steele N , Szlosarek P et al (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. LUNG CANCER, Vol. 115(Suppl 1) (pp S84-S84) View this article in WRRO
• Adams E, Cheng C-Y, Sacco J, Danson S, Corrie P, Nathan P, Szlosarek P, Upton J, Amuludun A & Toward T (2017) Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 5
• Fennell D, Kirkpatrick E, Cozens K, Danson S, Hanna G, Lester J, Lord J, Nye M, Ottensmeier C, Szlosarek P , Steele N et al (2017) PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. Journal of Thoracic Oncology, Vol. 12(11) (pp S2376-S2376)
• Wells G, Kohlmann A, Ratcliffe M, Wilson G, Dalton A & Danson S (2017) Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC). European Journal of Surgical Oncology, Vol. 43(11) (pp 2233-2233)
• Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2017) Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 43(11) (pp 2225-2225)
• Valicenti RK, Perets R, Lopez J, Danson S, Joensuu HT, Peer A, Harris SJ, Souza F, Ploeger B, Pereira KMC & Geva R (2017) Safety of Radium-223 + Paclitaxel in Cancer Patients with Bone Metastases: Results from an Open-Label, Multicenter Phase 1b Study. International Journal of Radiation Oncology*Biology*Physics, Vol. 99(2) (pp E269-E269)
• Danson S, Woll P, Edwards J, Blyth K, Fisher P, Roman J, Simpson K, Spavin R, Learmonth K & Conner J (2017) Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). Annals of Oncology, Vol. 28 (pp v122-v122)
• Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger BA, Pereira KMC & Perets R (2017) An open-label, multicenter Phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases. Annals of Oncology, Vol. 28 (pp v138-v138)
• Danson S, Woll P, Edwards J, Blyth K, Fisher P, Roman J, Simpson K, Spavin R, Learmonth K & Conner J (2017) Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). ANNALS OF ONCOLOGY, Vol. 28
• Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger BA, Pereira KMC & Perets R (2017) An open-label, multicenter Phase 1b study of radium-223+paclitaxel in cancer patients with bone metastases. ANNALS OF ONCOLOGY, Vol. 28
• Middleton MR, Schadendorf D, Danson S, Marshall E, Corrie P, Love SB, Mohammed SB, Scudder C & Goff M (2017) Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma. Clinical Trials
• Hiley CT, Ahmad T, Jamal-Hanjani M, Abbosh C, Ngai Y, Hackshaw A, Patterson P, Baijal S, Nicolson M, Lester JF , Krebs M et al (2017) Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp TPS9099-TPS9099)
• Corrie P, Marshall A, Lorigan P, Gore ME, Tahir S, Faust G, Kelly CG, Marples M, Danson S, Marshall E , Houston S et al (2017) Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp 9501-9501) View this article in WRRO
• Marshall R, Kakoudaki M, Danson SJ, Fisher PM, Hatton MQ, Lee CE, Das T, Bates E, Woll P & Taylor F (2017) 66: Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy. Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 27 January 2017. View this article in WRRO
• Kakoudaki M, Marshall R, Danson SJ, Fisher PM, Hatton MQ, Lee CE, Das T, Bates E, Woll P & Taylor F (2017) 67: Outcomes of patients in South Yorkshire who received maintenance pemetrexed treatment for non-squamous, non-small-cell cancer after induction chemotherapy with pemetrexed and cisplatin. Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 27 January 2017. View this article in WRRO
• Woll P, Gaunt P, Steele N, Ahmed S, Mulatero C, Shah R, Danson S, Hodgkinson E, James K, Watkins B , Fletcher P et al (2017) STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC. JOURNAL OF THORACIC ONCOLOGY, Vol. 12(1) (pp S704-S705)
• Silva S, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Cramp H, Taylor F, Cox A & Danson S (2016) Circulating cell-free DNA copy-number profiles as a biomarker in melanoma. European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S245-S245)
• Wilshaw V, Das T, Hatton N, Fisher PM, Lee CE, Danson SJ, Woll PJ & Hatton MQ (2015) 85: Systemic therapy in advanced NSCLC in the older patient: a network audit of non small cell lung cancer patients. Lung Cancer, Vol. 87 (pp S33-S33)
• Taylor F, Viggars A, Daniels S, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2015) 50: Outcomes of patients with malignant pleural mesothelioma treated with first line palliative cisplatin and pemetrexed chemotherapy, in South Yorkshire. Lung Cancer, Vol. 87 (pp S20-S20)
• Thomas SJ, Fisher K, Brown S, Snowden JA, Danson S & Zeidler M (2014) Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling. Blood, Vol. 124(21) (pp 4577-4577)
• Danson S, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz S , Kaye JA et al (2014) Lucabis: a Burden-Of-Illness Study in Patients with Stage Ib-Iiia Non-Small Cell Lung Cancer in France, Germany and the Uk. Annals of Oncology, Vol. 25 (pp iv415-iv415)
• Ottensmeier C, Galea I, Cross N, Maishman T, Hamid D, Cave J, Wheater M, Geldart T, Mulatero C, Potter V , Danson S et al (2014) A Novel Phase Ii Trial of Ipilimumab, Carboplatin and Etoposide (Ice) for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (Sclc). Annals of Oncology, Vol. 25 (pp iv516-iv516)
• Silva S, Colquitt J, Hatton MQ, Mohanamurali J, Lee C, Danson S, Fisher P & Woll P (2014) The use of pemetrexed for the first-line treatment of non-small cell lung cancer. LUNG CANCER, Vol. 83 (pp S13-S13)
• Woll P, Danson S, Edwards J, Goldsborough S, Fisher P & Conner J (2013) ONCOLYTIC HERPES VIRUS THERAPY FOR MESOTHELIOMA- A PHASE I STUDY OF INTRAPLEURAL ONCOLYTIC VIRUS HSV1716 (NCT01721018). JOURNAL OF THORACIC ONCOLOGY, Vol. 8 (pp S940-S941)
• Corrie P, Marshall A, Goonewardena M, Dunn JA, Middleton MR, Nathan PD, Gore ME, Davidson N, Nicholson S, Kelly CG , Marples M et al (2013) Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
• Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan PD et al (2013) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Corrie P, Marshall A, Goonewardena M, Dunn JA, Middleton MR, Nathan PD, Gore ME, Davidson N, Nicholson S, Kelly CG , Marples M et al (2013) AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, Vol. 31
• Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan P et al (2013) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. Journal of Clinical Oncology, Vol. 31
• Ahmad S, Qian W, Ellis SG, Khattak MA, Thillai K, Board RE, Nobes J, Dalgleish A, Grummet SA, Maraveyas A , Danson S et al (2013) Ipilimumab in the real world: the UK expanded access programme (EAP) experience in metastatic melanoma. Journal of Clinical Oncology, Vol. 31
• Talbot DC, Blackhall FH, Kowalski D, Ramlau R, Belper G, Grossi F, Lerchenmuller CA, Pinder MC, Mczger J, Danson S , Callies S et al (2013) A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).. Journal of Clinical Oncology, Vol. 31
• Sacco J, Nathan P, Danson S, Lorigan P, Nicholson S, Ottensmeier C, Corrie P, Steven N, Larkin J, Goodman A , Evans J et al (2013) Sunitinib versus dacarbazine as first line treatment in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, Vol. 31
• Bowen K, Walkington L, Evans LS & Danson SJ (2013) Thirty-day lung cancer mortality: a retrospective review of patients in the North Trent Cancer Network. LUNG CANCER, Vol. 79 (pp S14-S14)
• Woll PJ, Danson SJ, Edwards JG, Fisher PM & Conner J (2013) Oncolytic virus therapy for mesothelioma - a phase I trial of intrapleural seprehvir. LUNG CANCER, Vol. 79 (pp S34-S34)
• Best J, Young R, Ddamba J, Danson SJ, Fisher PM, Foran B, Hatton M, Lee C, Mohanamurali J & Woll PJ (2013) Blood transfusion requirements of NSCLC patients receiving chemotherapy in the BTOG2 trial. LUNG CANCER, Vol. 79 (pp S15-S16)
• Khan F, Ottensmeier C, Popat S & Danson SJ (2013) Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience. LUNG CANCER, Vol. 79 (pp S10-S11)
• Nugent L, Das T, Mohanamurali J, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2013) Gefitinib in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-TK mutation - North Trent Cancer Network experience. LUNG CANCER, Vol. 79 (pp S9-S9)
• Stansfield R, Mohanamurali J, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2013) Use of first line maintenance chemotherapy with pemetrexed in patients with non squamous non small cell lung cancer - North Trent Cancer Network experience. LUNG CANCER, Vol. 79 (pp S15-S15)
• Shaw H, Larkin J, Corrie P, Ellis S, Nobes J, Marshall E, Kumar S, Danson S, Plummer R & Nathan P (2012) IPILIMUMAB FOR ADVANCED MELANOMA IN AN EXPANDED ACCESS PROGRAMME (EAP): OCULAR, MUCOSAL AND ACRAL SUBTYPE UK EXPERIENCE. ANNALS OF ONCOLOGY, Vol. 23 (pp 374-374)
• Danson S, Rowland C, Eiser C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton M & Woll P (2012) Implications of smoking for quality of life and illness perceptions of lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Marshall E, Coupland S, Corrie P, Damato B, Danson S, Dobson L, Evans TRJ, Goodman A, Kalirai H, Jones S , Kumar S et al (2012) A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• O'Brien M, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier CHH, Danson S, Pallis AG , Hasan B et al (2012) Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Rowland C, Eiser C, Rowe R & Danson S (2012) Exploring quality of life of lung cancer patients and their partners by smoking history. PSYCHOLOGY & HEALTH, Vol. 27 (pp 110-110)
• Rowland C, Eiser C, Rowe R & Danson S (2012) Implications of smoking for quality of life and medical decision making in lung cancer patients. LUNG CANCER, Vol. 75 (pp S44-S45)
• Das TS, Hatton NFL, Danson S, Fisher PM, Lee C, Mohanamurali J, Woll PJ & Hatton MQF (2012) Systemic therapy in the elderly: A network audit of non small cell lung cancer patients. LUNG CANCER, Vol. 75 (pp S10-S10)
• Quinn AM, Blackhall F, Danson S, Wilson G, Brierley J, White E, Keeling C, Clamp A, Ashcroft L & Hasleton PS (2011) Extrapulmonary Small Cell Carcinoma: A Clinicopathological Study with Identification of Diagnostic Mimics. JOURNAL OF PATHOLOGY, Vol. 224 (pp S15-S15)
• Das T, Durkie M, Woll PJ, Hatton MQ, Mohanamurali J, Lee C, Fisher PM & Danson S (2011) Testing for epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based analysis in North Trent. LUNG CANCER, Vol. 71 (pp S13-S13)
• Alzouebi M, Fisher P, Woll PJ, Hatton MQ, Foran B, Mohanamurali J & Danson S (2010) Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. LUNG CANCER, Vol. 67 (pp S3-S3)
• Wheatley-Price P, Blackball F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian WD, Hackshaw A, Rudd R, Booton R , Danson S et al (2009) The influence of sex and histology on outcomes in non-small cell lung cancer: a pooled analysis of 5 randomized trials. J THORAC ONCOL, Vol. 4(9) (pp S286-S287)
• Woll PJ, Edwards JG, Danson S, Fisher PM, Matthews S & Conner J (2009) Oncolytic virus therapy for mesothelioma - a phase I trial proposal. LUNG CANCER, Vol. 63 (pp S26-S27)
• Danson S, Shaw K, Bruce L, Wadsley J, Fisher P, Foran B, Mohanamurali J, Trigg M, Joyce P, Woll PJ & Hatton MQ (2007) Outreach chemotherapy: convenience versus quality?. LUNG CANCER, Vol. 57 (pp S5-S5)
• Danson S, Johnson P, Ward T, Dawson M, Deneny O, Watson A, Jowle D, Sharpe P, Dive C & Ranson M (2007) Final results of a phase I clinical trial of the bioreductive drug RH1. Journal of Clinical Oncology, Vol. 25
• Danson S, Johnson P, Ward T, Dawson M, Denneny O, Cummings J, Jowle D, Howard E, Dive C & Ranson M (2005) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH1.. CLINICAL CANCER RESEARCH, Vol. 11(24) (pp 9150S-9150S)
• Danson S, Clamp A, Davidson S, Wylie J, Ashcroft L, Wardley A, Anderson H, Hasleton P & Thatcher N (2005) Extrapulmonary small cell carcinoma: Our experience over ten years. LUNG CANCER, Vol. 49 (pp S317-S317)
• O'Byrne K, Clarke L, Dunlop D, Ranson M, Danson S, Botwood N & Carbone D (2004) Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 641S-641S)
• Ward TH, Danson S, Dawson M, McGrath H, Denneny O, Cummings J, Dive C & Ranson M (2004) Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S60-S60)
• Wardley A, Danson S, Clayton A, Clemons M, Waine S, Burt P, Stewart A, Wilkinson P, Welch R, Magee B & Howell A (2002) High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer centre. Journal of Clinical Oncology
• Danson S, Arance A, Lorigan P, Clamp A, Hodgetts J, Lomax L, Ashcroft L & Thatcher N (2002) A randomized study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Journal of Clinical Oncology
• Lorigan P, Danson S, Clamp A, Hodgetts J, Lomax L, Ashcroft L, Middleton MR & Thatcher N (2002) Toxicity of temozolomide with response modifiers in metastatic malignant melanoma. BRIT J CANCER, Vol. 86 (pp S68-S68)
• Danson S, Clemons M, Middleton MR, O'Bryne K, Hassan J, Anderson H, Burt P, Stout R, Swindell R, Dowd I , Beresford C et al (2001) A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
• Valle JW, Danson S, Burgess A, Meehan M & Hawkins RE (2001) The use of sandostatin-LAR in the treatment of carcinoid syndrome - experience from a single centre. Journal of Clinical Oncology
• Danson S, Clemons M, Middleton MR, O'Bryne K, Hassan J, Anderson H, Burt P, Stout R, Swindell R, Dowd I , Beresford C et al (2001) A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
• Danson SJ, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz S , Kaye JA et al () LuCaBIS: A Burden-of-Illness Study in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer in France, german and the UK.. Annals of Oncology(25 (supp 4)) (pp iv 409-iv 416). Madrid, 26 September 2014 - 30 September 2014.

Reports

• Danson S (2009) Second line chemotherapy for small cell lung cancer

Other

• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Data from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) MESO-02 Trial Protocol from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Data Protocol from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) Supplementary Data from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 2 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Data Protocol from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) Supplementary Data from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Data from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 3 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 1 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) MESO-02 Trial Protocol from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) Data from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 4 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Tables and Methods from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 3 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) Data from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 2 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 1 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Tables and Methods from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
• Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) Supplementary Figure 4 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).